Testing a painless scan to study liver spots in cirrhosis
Part of Digestive system clinical trials.
This trial studies “focal liver lesions,” meaning specific spots in the liver, using a non-invasive (no surgery or biopsy) approach. It may help doctors better understand what these spots are in people who have cirrhosis.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have liver cirrhosis (scarring of the liver).
- You have one or more specific spots (“focal liver lesions”) seen in your liver.
- You are able and willing to sign consent to join the study.
- You must be 18 years or older.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks for better ways to detect liver scarring (fibrosis) in people with long-term liver disease. It may help find problems earlier.
This study looks at how liver cirrhosis shows up on non-invasive imaging like CT scans, and how those findings relate to outcomes. It may help researchers better understand what scan patterns could signal disease severity.
This study looks at non-invasive tests (tests that don’t require surgery) to see whether they can diagnose and predict how chronic liver disease will worsen over time. If you may have chronic liver disease, these tests could help doctors follow your condition more accurately.
This study compares two non-invasive approaches to diagnose advanced liver scarring in people with non-alcohol-related fatty liver disease (NAFLD). It may help confirm which test strategy finds advanced scarring without needing a biopsy for everyone.
This study follows people with cirrhosis to see how best to detect liver cancer early. If you qualify, you may receive regular monitoring that could help find liver cancer sooner, when treatment is more likely to work.
This study looks at how your body uses protein in your muscles when you have cirrhosis (a scarred liver). It uses a special “tracer” method (a substance that can be tracked) and may help researchers better understand muscle loss in people with milder cirrhosis.
Hear when a new Liver Cirrhoses trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.